Alx Oncology Holdings (ALXO) Other Non Operating Income (2020 - 2026)
Alx Oncology Holdings (ALXO) posted Other Non Operating Income of $188000.0 for Q1 2026, down 92.37% sequentially from $2.5 million in Q4 2025, and up 1809.09% YoY from $9847.6 in Q1 2025.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Other Non Operating Income (2020 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Other Non Operating Income for 7 years, with the latest figure at $188000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 1809.09% year-over-year to $188000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (up 15647.06% YoY) and the FY2025 annual result came in at $2.4 million, up 12320.0% from the prior year.
- Other Non Operating Income eased to $188000.0 in Q1 2026 per ALXO's latest filing, from $2.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $19.0 million in Q4 2022 and troughed at -$14000.0 in Q1 2024.
- A 5-year average of $1.7 million and a median of -$1000.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income slumped 350.0% in 2022, then soared 246400.0% in 2025.
- Over 5 years, Other Non Operating Income stood at $19.0 million in 2022, then tumbled by 65.01% to $6.6 million in 2023, then slumped by 100.02% to -$1000.0 in 2024, then jumped by 246400.0% to $2.5 million in 2025, then tumbled by 92.37% to $188000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $188000.0, $2.5 million, and -$6000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Alx Oncology Holdings | 274.67 Mn | 274.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -904,000.00 |
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 2.46 Mn |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 6.64 Mn |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | 324,000.00 |
| Mar 31, 2023 | 95,000.00 |
| Dec 31, 2022 | 18.97 Mn |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | -8,000.00 |
| Dec 31, 2021 | 11.04 Mn |
| Sep 30, 2021 | -12,000.00 |